DiaMedica Therapeutics Inc. (DMAC)
NASDAQ (CM) NASDAQ (CM) Primary 
Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 130% in DiaMedica Therapeutics (DMAC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy
DiaMedica Therapeutics (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript
DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript
DiaMedica Therapeutics Q2 Earnings Call Highlights
DiaMedica Therapeutics NASDAQ: DMAC said its second-quarter progress centered on advancing DM199 across early-onset fetal growth restriction (FGR), preeclampsia and acute ischemic stroke, while the company reported a cash runway it expects to extend through 2027.
DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript
DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript
DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript
DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript
DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript
DiaMedica Therapeutics Inc. ( DMAC ) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Dietrich Pauls - President, CEO & Director Julie Krop - Chief Medical Officer Scott Kellen - CFO & Corporate Secretary Conference Call Participants Stacy Ku - TD Cowen, Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Matthew Caufield - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Q3, 2025 Earnings Conference Call.
DiaMedica Therapeutics, Inc. (DMAC) is a Great Momentum Stock: Should You Buy?
Does DiaMedica Therapeutics, Inc. (DMAC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect?
The mean of analysts' price targets for DiaMedica Therapeutics (DMAC) points to an 114.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia
Positive interim phase 1a data for DM199 in preeclampsia establishes proof-of-concept and supports expansion to phase 1b and fetal growth restriction studies. DM199's mechanism targets key factors in preeclampsia, offering a potential best-in-class, disease-modifying therapy in a large, underserved market. Strong cash position of $60.1 million extends runway into 2H 2027, supporting ongoing and expanded clinical development.
DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Dietrich John Pauls - President, CEO & Director Julie Krop - Chief Medical Officer Scott Kellen - CFO & Corporate Secretary Conference Call Participants Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Q2 2025 Earnings Conference Call. An audio recording of this webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.
DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Matthew Caufield - H.C. Wainwright Chase Knickerbocker - Craig-Hallum Operator Good morning ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2025 Conference Call.
